News

  • 17 January 2018

    FDA accepts Sandoz’s BLA for biosimilar adalimumab

    The US Food and Drug Administration (FDA) has accepted to review the biologics licence application (BLA) submitted by Sandoz, division of Novartis, for proposed biosimilar adalimumab to reference medicine Humira.

  • 16 January 2018

    FDA approves Lynparza to treat inherited breast cancer

    The US Food and Drug Administration (FDA) has approved the use of AstraZeneca’s Lynparza (olaparib tablets) for the treatment of certain types of breast cancer that have metastasized and those...